This in-person* workshop is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes role plays, demonstrations, case examples, and experiential learning opportunities.

This workshop has an enrolment limited to 70 participants. Lead trainers Drs Gorman & Nielson as well as four assisting trainers will be present, including members of the Mindspace Psychedelics team. This workshop has been offered nationally and internationally over 10 times in the last 2 years and has routinely sold out and generated a waiting list. Upon completion, participants will be offered the opportunity to join the presenters’ google group with over 500 past program participants for networking and continued collaboration.

This two-day workshop is part of a three-day program that also includes an experiential day of mindfulness practices for psychedelic integration. To register for the full three days please see this event listing. A limited number of Sunday only tickets for Mindfulness Skills for Integration are available for people who have previously attended 101 & 102. We strongly encourage participants to take the full 3-day workshop.

*As of posting the intention is to offer this program in-person. In the event that public health policy does not allow us to offer it in person as of thirty-days prior to the event, it will be rescheduled for a later date—not moved to an online format.

Psychedelics 101:

Your patients are curious and so are you: What is all this about psychedelics being used for treatment of addiction and trauma? This session gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy. This program includes overview of recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.

Learning Objectives:

  • Discuss the historical justifications for psychedelic clinical research
  • Describe key theoretical approaches to psychedelic-assisted therapy
  • Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients.
  • Compare psychedelic integration psychotherapy to integration in peer and shamanic settings

Psychedelics 102:

What are psychedelic harm reduction and integration and how can they occur in a clinical setting? This session focuses on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues.

Learning Objectives:

  • Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
  • Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use
  • List contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
  • Describe the role of the therapist in an individual’s integration psychotherapy process

Continuing Education and Accreditation Information

For Quebec mental health professionals

This course has been approved by the OPQ for 12 hours of continuing education credits, and the cost is included in the program price.

For health professionals in the US

Continuing Education Credits for Health Professionals (CE)

Continuing Education credits are offered at an additional cost of $65 USD, payable to the presenters by credit card through a separate invoice.

  • CE credits for psychologists are provided by the Spiritual Competency Resource Center (SCRC) which is co-sponsoring this program. The Spiritual Competency Resource Center is approved by the American Psychological Association to sponsor continuing education for psychologists. The Spiritual Competency Resource Center maintains responsibility for this program and its content.
  • The California Board of Behavioral Sciences accepts CE credits for LCSW, LPCC, LEP, and LMFT license renewal for programs offered by approved sponsors of CE by the American Psychological Association.
  • LCSWs, MFTs, and other mental health professionals from states other than California need to check with their state licensing board as to whether or not they accept programs offered by approved sponsors of CE by the American Psychological Association.
  • SCRC is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California.
  • For questions about receiving your Certificate of Attendance, contact elizabeth@fluence8.com. For questions about CE, visit www.spiritualcompetency.com or contact David Lukoff, PhD at CE@spiritualcompetency.com.

For Physicians and Medical Professionals (CME)

CME accreditation is available at an additional cost of $350 USD, payable to the presenters by credit card through a separate invoice.

In support of improving patient care, this activity has been planned and implemented by Cine-Med and Medical Resource Association.

Cine-Med is jointlyaccredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Ciné-Med designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructors


Ingmar Gorman, Ph.D.

Ingmar Gorman, Ph.D., is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Director of the Psychedelic Education and Continuing Care Program, where he leads groups, trainings, and works with individual clients. Dr. Gorman is also site co-principal Investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for post-traumatic stress disorder. He is a NIH funded fellow at New York University and a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics.

Elizabeth Nielson, Ph.D.

Dr. Elizabeth Nielson is a psychologist with a holistic, compassionate, and integrative approach to psychotherapy. She specializes in treating addictive and mood disorders with a blend of of mindfulness-based interventions, dialectical behavior therapy, psychodynamic therapy, community reinforcement and family training (CRAFT), and principles of psychedelic-assisted therapy. Dr. Nielson is part of the Experimental Therapeutics Research Laboratory at NYU Langone School of Medicine where she is a therapist on the psilocybin-assisted treatment for alcohol dependence trial and on the MDMA-assisted psychotherapy for PTSD clinical trials.